Lynn A. Fussner
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lynn A. Fussner.
Liver Transplantation | 2015
Lynn A. Fussner; Julie K. Heimbach; Chun Fan; Ross A. Dierkhising; Elizabeth Coss; Michael D. Leise; Kymberly D. Watt
The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity and metabolic syndrome (MS), define the cumulative incidence of CVD, and characterize risk factors associated with these comorbidities after LT. A retrospective review of 455 consecutive LT recipients from 1999 to 2004 with an 8‐ to 12‐year follow‐up was performed. Obesity increased from 23.8% (4 months) to 40.8% (3 years) after LT. Increase in body mass index predicted MS at 1 year after LT (odds ratio, 1.1; P < 0.001, per point). CVD developed in 10.6%, 20.7%, and 30.3% of recipients within 1, 5, and 8 years, respectively. Age, diabetes, hypertension, glomerular filtration rate < 60 mL/minute, prior CVD, ejection fraction < 60%, left ventricular hypertrophy, and serum troponin (TN) > 0.07 ng/mL were associated with CVD on univariate analysis. Age (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.01‐1.06; P = 0.019), diabetes (HR, 1.78; 95% CI, 1.09‐2.92; P = 0.022), prior history of CVD (HR, 2.46; 95% CI, 1.45‐4.16; P < 0.001), and serum TN > 0.07 ng/mL (HR, 1.98; 95% CI, 1.23‐3.18; P = 0.005) were independently associated with CVD in the long term. Smoking history (ever), sex, hyperlipidemia, and serum ferritin levels were not predictive of CVD. Tacrolimus use versus noncalcineurin‐based immunosuppression (HR, 0.26; 95% CI, 0.14‐0.49; P < 0.001) was associated with reduced risk of CVD but not versus cyclosporine (HR, 0.67; 95% CI, 0.30‐1.49; P = 0.322). CVD is common after LT. Independent of MS, more data are needed to identify nonconventional risk factors and biomarkers like serum TN. Curbing weight gain in the early months after transplant may impact MS and subsequent CVD in the long term. Liver Transpl 21:889‐896, 2015.
Arthritis & Rheumatism | 2016
Lynn A. Fussner; Amber M. Hummel; Darrell R. Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R. Snyder; Gary S. Hoffman; Cees G. M. Kallenberg; Carol A. Langford; Peter A. Merkel; Paul A. Monach; Philip Seo; Robert Spiera; E. William St. Clair; Nadia K. Tchao; John H. Stone; Ulrich Specks
Relapse following remission is common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), particularly with ANCAs directed at proteinase 3 (PR3). This study was undertaken to evaluate the association of an increase in PR3‐ANCA level with subsequent relapse.
Liver International | 2014
Lynn A. Fussner; Michael R. Charlton; Julie K. Heimbach; Chun Fan; Ross A. Dierkhising; Elizabeth Coss; Kymberly D. Watt
Chronic kidney disease (CKD) after liver transplant (LT) is associated with increased long‐term mortality. The impact of gender on CKD before and after LT is unknown. To further define risk factors and analyse gender differences in the incidence and progression of CKD after liver transplant.
Liver Transplantation | 2015
Lynn A. Fussner; Vivek N. Iyer; Rodrigo Cartin-Ceba; Grace D Lin; Kymberly D. Watt; Michael J. Krowka
Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are pulmonary vascular complications of portal hypertension with divergent clinicopathologic features and management. The presence of intrapulmonary vascular dilatations (IPVDs), detected by agitated saline contrast‐enhanced transthoracic echocardiography (cTTE), is an essential feature of HPS but is not typically characteristic of POPH. Although IPVDs have been reported rarely in POPH, the prevalence and significance of this finding have not been systematically studied. We conducted a retrospective chart review of 80 consecutive patients diagnosed with POPH from January 1, 2002 to June 30, 2014 with documentation of cTTE findings, pulmonary hemodynamics, oxygenation, and survival. A total of 34 of the 80 patients (42%) underwent cTTE during initial diagnosis of POPH. IPVDs were detected in 20/34 patients (59%); intracardiac shunting was detected in 9/34 patients (26%; 4 also had IPVDs); and 9 patients (26%) had negative cTTE with no evidence of IPVD or intracardiac shunting. Patients with IPVD had decreased survival as compared to those without IPVD (P = 0.003), a trend that persisted after exclusion of liver transplant recipients (P = 0.07). The IPVD group had a trend toward higher Model for End‐Stage Liver Disease score with and without incorporating sodium (MELD or MELD‐Na; P = 0.05 for both). The right ventricular index of myocardial performance (RIMP) was lower in the IPVD group (median, 0.4 versus 0.6; P = 0.006). Patients with moderate or large IPVDs (n = 6) had worse oxygenation parameters (partial pressure of arterial oxygen, diffusing capacity of the lung for carbon monoxide, and alveolar‐arterial oxygen gradient) as compared to the rest of the cohort. Unexpectedly, IPVDs were frequently documented in POPH and associated with decreased survival. To further understand this observation, we recommend screening for IVPD in all patients with POPH. Liver Transpl 21:1355‐1364, 2015.
Current Gastroenterology Reports | 2016
Lynn A. Fussner; Michael J. Krowka
Portopulmonary hypertension (POPH) is a form of pulmonary arterial hypertension occurring in the setting of portal hypertension with or without hepatic cirrhosis. The presence of both portal and pulmonary vascular disease contributes to complicated hemodynamics and therapeutic challenges, though the severities do not appear to correlate directly. Diagnosis of POPH, and distinction from the commonly observed hyperdynamic state of end-stage liver disease, is typically accomplished with an initial screening transthoracic echocardiogram, followed by right heart catheterization for confirmation of hemodynamic parameters. Though few studies have directly evaluated use in POPH, pulmonary artery-directed therapy is the cornerstone of management, along with consideration of liver transplantation. Perioperative and long-term outcomes are variable, but uniformly worse in the setting of uncontrolled pulmonary pressures. Risk stratification and optimal patient selection for these interventions are areas of ongoing investigation.
Current Opinion in Rheumatology | 2015
Lynn A. Fussner; Ulrich Specks
Purpose of reviewThe role of serial antineutrophil cytoplasmic antibody (ANCA) measurements to guide immunosuppressive therapy in pauci-immune vasculitis is an area of ongoing controversy. Evidence elucidating the relationship between ANCA levels and disease activity continues to grow. Recent findingsThe finding that proteinase 3-ANCA and myeloperoxidase-ANCA-associated diseases differ genetically has challenged the traditional classification and study of pauci-immune vasculitis. Multiple studies have also found that the clinical features and course of disease differ by ANCA antigen specificity more than clinical diagnosis. Advances in diagnostic assays and new techniques for the evaluation of ANCA levels over time have yielded improved assay performance in specific subsets of patients. In addition, increasing use of rituximab has added to our understanding of the relationship of ANCA levels to B-cell counts and disease relapse, which may differ by treatment regimen. SummaryThe relationship between ANCA levels and disease activity is impacted by multiple factors, including antigen specificity, disease manifestations, clinical assay, and therapeutic regimen. Each of these must be taken into account when determining the significance of ANCA levels during long-term follow-up of pauci-immune vasculitis.
Mayo Clinic Proceedings | 2013
Lynn A. Fussner; Kimberly N. Harer; Thomas H. Poterucha
51-year-old man with a history of hyperlipidemia presented to the outpatient internal medicine clinic with a 3-week history of tinnitus. He described a “whoosh-whoosh” sound in his right ear that was constant and that increased in intensity with exertion. It was increasing in severity duringtheprevious3weeksandwasassociated with a new-onset, progressive, right-sided headache.Theheadachewasstabbinginnature and occasionally awakened him from sleep. He denied hearing loss, vertigo, vision changes, syncope, and recent illness or trauma. His medications included acetaminophen and naproxen as needed. He had a smoking history of10pack-years,withcessation13yearsbefore presentation; acknowledged drinking 1 to 2 alcoholic beverages per day; denied illicit drug use; and worked as a salesman driving 250 miles per day. On examination, the patient was afebrile, with a blood pressure of 129/82 mm Hg, a pulse rate of 68 beats/min, and a respiratory rate of 18 breaths/min. He appeared comfortable and in no acute distress. He had no scleral injection, and results of funduscopic examination were normal. The external auditory canals and tympanic membranes were visualized and normal bilaterally. Results of Weber and Rinne testing were normal. Cranial nerves II to XII were otherwise intact bilaterally, and the results of the remainder of the neurologic examination were within normal limits. No carotid bruits were auscultated. Heart, lung, abdominal, and lymphatic examination findings were unremarkable.
Journal of the American College of Cardiology | 2017
Cristina Di Stefano; Giulia Bruno; Gayatri Acharya; Rachel J. Le; Lynn A. Fussner; Patompong Ungprasert; Leslie T. Cooper; Lori Blauwet; Patricia A. Pellikka; Jay Ryu; Eva M. Carmona; Hector R. Villarraga
Chest | 2016
Lynn A. Fussner; Erin Karlstedt; Nowell M. Fine; Sanjay Kalra; Eva M. Carmona; James P. Utz; Debra Isaac; Leslie T. Cooper
Chest | 2015
Lynn A. Fussner; Eva M. Carmona